ArticleThe oncologist2026
Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe proto-oncogene rearranged during transfection (RET) mutation can influence tumor immunogenicity and regulate immune responses through multiple pathways. Herein, we performed an in-depth bioinformatic and clinical analysis to systematically evaluate the attributes of RET mutation and their interconnections with outcomes in pan-cancer immune checkpoint blockade (ICB) therapeutic interventions.
methodsThe predictive significance of RET mutation was evaluated in a discovery cohort comprising 1406 patients with 6 tumor types, and the findings were verified in an independent cohort of 1524 individuals representing 9 tumor types. Utilizing The Cancer Genome Atlas (TCGA), we retrieved multi-omics data and further investigated both intrinsic and extrinsic immune response mechanisms behind the RET mutation.
resultsAmong 2930 immune checkpoint inhibitor (ICI)-treated patients with 11 tumor types, the presence of RET mutation showed a significant association with favorable overall survival (HR, 0.60; 95% CI, 0.48-0.75; P < .001) and objective response rate (44.9% vs. 25.7%; P < .001). Furthermore, the frequencies of 6 mutational signatures related to immunotherapy outcomes, changed significantly in RET-mutant tumors. Additional multi-omics analysis on intrinsic and extrinsic immune landscapes elucidated that the RET mutation could enrich immune cell infiltration besides improving tumor immunogenicity, alongside immune responses.
conclusionsRearranged during transfection mutation may enhance anti-tumor immunity and function as an independent biomarker for promising outcomes across multiple cancer types treated with ICB. These findings have the potential to inform clinical decision-making, guide personalized immunotherapy strategies, and contribute to the advancement of precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.